BioWorld MedTech

May 31, 2017

Saluda Medical evokes funding from two industry heavyweights in series D round

Saluda Medical Pty Ltd. is spreading its roots in both the neuromodulation space and the developing bioelectronics medicine market with its latest funding round. Read More

Intuitive surges as robotic surgery acceptance settles in, but can it maintain momentum?

Ra Medical's laser ablative PAD treatment is now FDA-approved

FDA rejects Sunovion Pharmaceuticals' new drug app for COPD drug and nebulizer

Appointments and advancements

Other news to note

Financings

Product briefs

Medical Device Daily's Oncology Extra

Today's news in brief

BioWorld

BioWorld briefs for March 27, 2026.

ADPD 2026: Can we prevent dementia? Scientists quantify it

BioWorld

Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...

Illustration of Alzheimer's disease in the brain

ADPD 2026: Three inflection points to target Alzheimer’s disease

BioWorld Science

A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...

Emerging therapeutic strategies for Parkinson’s at ADPD 2026

BioWorld

Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...

News in brief

BioWorld Asia

BioWorld Asia briefs for March 24, 2026